EGFR and non-small cell lung carcinoma: Interestingly, MALAT1 is significantly higher in plasma from NSCLC patients who have EGFR mutation compared to EGFR WT patients,225 suggesting that lncRNA expression, incorporation into exosomes, or release into blood could potentially serve as a diagnostic or predictive biomarker.